Platelet response to prasugrel and clopidogrel loadinig doses in elective PCI patients

Platelet response to prasugrel and clopidogrel loadinig doses in elective PCI patients - Comparison of platelet responses to different thienopyridines

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017624

Enrollment

Registered

2015-05-21

Start date

2014-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective PCI

Interventions

prasugrel group clopidogrel group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Stable angina pectoris patient scheduled for elective coronary artery stenting. (2)Patient who takes aspirin. (3)One of the tests (cardiac computed tomography, stress technetium myocardial scintigraphy, exercise tredmil test) is positive. (4)Patient who give informed consent to this study.

Exclusion criteria

Exclusion criteria: (1)Concomitant use of other antiplatelet drugs other than aspirin. (2)Participation in other clinical trial. (3)Platelet counts of <10x107/ml or >40x107/ml (4)Malignant disease or autoimmune disease. (5)Judgment by physician that a patient is inappropriate to enroll the study. (6)Patient who have communication difficulty.

Design outcomes

Primary

Measure	Time frame
Responses of platelets to the treatment with prasugrel and clopidogrel.	—

Secondary

Measure	Time frame
To investigate the frequency of bleeding complication such as gross hematuria,subcutaneous bleeding,hemoglobin change after percutaneous coronary intervention.	—

Countries

Japan

Contacts

Public ContactSatoshi Niijima

Jichi Medical University School of Medicine Division of Cardiovascular Medicine

r0742sn@jichi.ac.jp0285-44-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026